Mitogen-activated protein kinase phosphatase 1 is involved in tamoxifen resistance in MCF7 cells

Ma,Gang; Pan,Yixia; Zhou,Can; Sun,Ruifang; Bai,Jingjing; Liu,Peijun; Ren,Yu; He,Jianjun

doi:10.3892/or.2015.4244

Mitogen-activated protein kinase phosphatase 1 is involved in tamoxifen resistance in MCF7 cells

Authors:
- Gang Ma
- Yixia Pan
- Can Zhou
- Ruifang Sun
- Jingjing Bai
- Peijun Liu
- Yu Ren
- Jianjun He
View Affiliations

Affiliations: Department of Breast Surgery, The First Affiliated Hospital, Medicine College of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Gynecology, Northwest Women and Childrens Hospital, Xi'an, Shaanxi 710061, P.R. China, Department of Pathology, Medicine College of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Shaanxi Province People's Hospital, Xi'an, Shaanxi 710068, P.R. China, Department of Translational Medicine Center, The First Affiliated Hospital, Medicine College of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: September 2, 2015 https://doi.org/10.3892/or.2015.4244
Pages: 2423-2430

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tamoxifen resistance is a major clinical problem for ER-positive breast cancer, but the underlying mechanism is not completely elucidated. In the present study, we reported that mitogen-activated protein kinase (MAPK) phosphatase 1 (MKP-1), a member of the family of MKPs, is involved in tamoxifen resistance. We found that MKP1 expression increased in tamoxifen resistant MCF7 cells. To explore the possible role of MKP1 in tamoxifen resistance, siRNA targeting MKP1 was transfected into tamoxifen resistant MCF7 cells. To our surprise, knockdown of MKP-1 promoted cell death induced by tamoxifen. On the other hand, the MKP1 overexpressed MCF7 cell clone was established and MKP1 overexpression effectively attenuated MCF7 cell death induced by tamoxifen. In addition, we revealed that MKP1 inhibited tamoxifen‑mediated JNK activation in tamoxifen resistant MCF7 and MCF7 cells, and by this mechanism MKP1 was able to inhibit tamoxifen-induced cell death. We also showed that combined appliaction of MKP1 inhibitor triptolide and tamoxifen can effectively increase tamoxifen sensitivity in tamoxifen resistant MCF7 cells. Collectively, our results indicated that MKP-1 can attenuate tamoxifen-induced cell death through inhibiting the JNK signal pathway, which represents a novel mechanism of tamoxifen resistance in MCF7 cells.

View Figures

View References

1	Cancer Genome Atlas N: Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar
2	Osborne CK and Schiff R: Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 62:233–247. 2011. View Article : Google Scholar
3	Osborne CK and Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med. 339:1609–1618. 1998. View Article : Google Scholar : PubMed/NCBI
4	Riggins RB, Schrecengost RS, Guerrero MS and Bouton AH: Pathways to tamoxifen resistance. Cancer Lett. 256:1–24. 2007. View Article : Google Scholar : PubMed/NCBI
5	García-Becerra R, Santos N, Díaz L and Camacho J: Mechanisms of resistance to endocrine therapy in breast cancer: Focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci. 14:108–145. 2012. View Article : Google Scholar
6	Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
7	Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM and Nicholson RI: Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 96:131–146. 2006. View Article : Google Scholar
8	Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK and Dowsett M: Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 23:2469–2476. 2005. View Article : Google Scholar : PubMed/NCBI
9	Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA and Cross-Doersen DE: Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ. 7:351–359. 1996.PubMed/NCBI
10	Mandlekar S, Yu R, Tan TH and Kong AN: Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res. 60:5995–6000. 2000.PubMed/NCBI
11	Theodosiou A and Ashworth A: MAP kinase phosphatases. Genome Biol. 3:S30092002. View Article : Google Scholar
12	Camps M, Nichols A and Arkinstall S: Dual specificity phosphatases: A gene family for control of MAP kinase function. FASEB J. 14:6–16. 2000.PubMed/NCBI
13	Wu JJ, Roth RJ, Anderson EJ, Hong EG, Lee MK, Choi CS, Neufer PD, Shulman GI, Kim JK and Bennett AM: Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. Cell Metab. 4:61–73. 2006. View Article : Google Scholar : PubMed/NCBI
14	Zhao Q, Wang X, Nelin LD, Yao Y, Matta R, Manson ME, Baliga RS, Meng X, Smith CV, Bauer JA, et al: MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J Exp Med. 203:131–140. 2006. View Article : Google Scholar
15	Wancket LM, Frazier WJ and Liu Y: Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease. Life Sci. 90:237–248. 2012. View Article : Google Scholar :
16	Li M, Zhou JY, Ge Y, Matherly LH and Wu GS: The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. J Biol Chem. 278:41059–41068. 2003. View Article : Google Scholar : PubMed/NCBI
17	Sánchez-Pérez I, Martínez-Gomariz M, Williams D, Keyse SM and Perona R: CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene. 19:5142–5152. 2000. View Article : Google Scholar : PubMed/NCBI
18	Wang Z, Xu J, Zhou JY, Liu Y and Wu GS: Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Res. 66:8870–8877. 2006. View Article : Google Scholar : PubMed/NCBI
19	Small GW, Shi YY, Higgins LS and Orlowski RZ: Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res. 67:4459–4466. 2007. View Article : Google Scholar : PubMed/NCBI
20	Wang Z, Zhou JY, Kanakapalli D, Buck S, Wu GS and Ravindranath Y: High level of mitogen-activated protein kinase phosphatase-1 expression is associated with cisplatin resistance in osteosarcoma. Pediatr Blood Cancer. 51:754–759. 2008. View Article : Google Scholar : PubMed/NCBI
21	Brünner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME and Clarke R: MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res. 53:3229–3232. 1993.PubMed/NCBI
22	Takeuchi K, Shin-ya T, Nishio K and Ito F: Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase. FEBS J. 276:1255–1265. 2009. View Article : Google Scholar : PubMed/NCBI
23	Mandlekar S and Kong AN: Mechanisms of tamoxifen-induced apoptosis. Apoptosis. 6:469–477. 2001. View Article : Google Scholar : PubMed/NCBI
24	Bogush T, Dudko E, Bogush E, Polotsky B, Tjulandin S and Davydov M: Tamoxifen non-estrogen receptor mediated molecular targets. Oncol Rev. 6:e152012. View Article : Google Scholar : PubMed/NCBI
25	Madeo A, Vinciguerra M, Lappano R, Galgani M, Gasperi-Campani A, Maggiolini M and Musti AM: c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells. Oncogene. 29:978–991. 2010. View Article : Google Scholar
26	Wang N, Li Z, Tian F, Feng Y, Huang J, Li C and Xie F: PKCα inhibited apoptosis by decreasing the activity of JNK in MCF-7/ADR cells. Exp Toxicol Pathol. 64:459–464. 2012. View Article : Google Scholar
27	Chen P, Li J, Barnes J, Kokkonen GC, Lee JC and Liu Y: Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J Immunol. 169:6408–6416. 2002. View Article : Google Scholar : PubMed/NCBI
28	Zhao Q, Shepherd EG, Manson ME, Nelin LD, Sorokin A and Liu Y: The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: Attenuation of proinflammatory cytokine biosynthesis via feedback control of p38. J Biol Chem. 280:8101–8108. 2005. View Article : Google Scholar
29	Obrero M, Yu DV and Shapiro DJ: Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem. 277:45695–45703. 2002. View Article : Google Scholar : PubMed/NCBI
30	Wang HY, Cheng Z and Malbon CC: Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett. 191:229–237. 2003. View Article : Google Scholar : PubMed/NCBI
31	Rojo F, González-Navarrete I, Bragado R, Dalmases A, Menéndez S, Cortes-Sempere M, Suárez C, Oliva C, Servitja S, Rodriguez-Fanjul V, et al: Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clin Cancer Res. 15:3530–3539. 2009. View Article : Google Scholar : PubMed/NCBI
32	Wang J, Zhou JY and Wu GS: ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res. 67:11933–11941. 2007. View Article : Google Scholar : PubMed/NCBI
33	Rabenoelina F, Semlali A, Duchesne MJ, Freiss G, Pons M and Badia E: Effect of prolonged hydroxytamoxifen treatment of MCF-7 cells on mitogen activated kinase cascade. Int J Cancer. 98:698–706. 2002. View Article : Google Scholar : PubMed/NCBI
34	Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM and El-Ashry D: Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res. 66:3903–3911. 2006. View Article : Google Scholar : PubMed/NCBI